3U30
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 3u30 by Molmil](/molmil-images/mine/3u30) | Crystal structure of a linear-specific Ubiquitin fab bound to linear ubiquitin | Descriptor: | Heavy chain Fab, Light chain Fab, linear di-ubiquitin | Authors: | Matsumoto, M.L, Dong, K.C, Yu, C, Phu, L, Gao, X, Hannoush, R.N, Hymowitz, S.G, Kirkpatrick, D.S, Dixit, V.M, Kelley, R.F. | Deposit date: | 2011-10-04 | Release date: | 2012-01-18 | Last modified: | 2023-09-13 | Method: | X-RAY DIFFRACTION (2.428 Å) | Cite: | Engineering and structural characterization of a linear polyubiquitin-specific antibody. J.Mol.Biol., 418, 2012
|
|
7MFR
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7mfr by Molmil](/molmil-images/mine/7mfr) | Crystal Structure of a Fab fragment bound to peptide GGM | Descriptor: | Antibody fragment - Heavy Chain of fab, Antibody fragment - Light Chain of fab, GLY-GLY-MET, ... | Authors: | Sudhamsu, J. | Deposit date: | 2021-04-10 | Release date: | 2021-06-16 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.848 Å) | Cite: | Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W. Nat Commun, 12, 2021
|
|
3OJ4
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 3oj4 by Molmil](/molmil-images/mine/3oj4) | |
3OJ3
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 3oj3 by Molmil](/molmil-images/mine/3oj3) | |
3NOB
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 3nob by Molmil](/molmil-images/mine/3nob) | |
3PTF
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 3ptf by Molmil](/molmil-images/mine/3ptf) | |
7R7R
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7r7r by Molmil](/molmil-images/mine/7r7r) | Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol) | Descriptor: | (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol, ALK tyrosine kinase receptor | Authors: | McTigue, M. | Deposit date: | 2021-06-25 | Release date: | 2022-06-29 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.935 Å) | Cite: | Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer, 3, 2022
|
|
7R7K
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7r7k by Molmil](/molmil-images/mine/7r7k) | |
4JLP
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 4jlp by Molmil](/molmil-images/mine/4jlp) | |
4JLO
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 4jlo by Molmil](/molmil-images/mine/4jlo) | |